Home > Formulary : Adult > Recent Decisions > 2024 >
Decisions 26th March 2024
Decisions 26th March 2024
New Drug Request Approvals
- Aerobika® oscillating positive expiratory pressure device (TLS Amber Specialist Recommended) for chest airways mucus clearance for adult patients following assessment/recommendation by a chest clearance competent respiratory practitioner. It is expected that patients will have been provided training on how to use the device by the practitioner recommending the device. These devices are expected to have a 12 month replacement life.
- Acetylcisteine (Acepiro®) 600mg effervescent tablets (TLS Green) for use as a mucolytic agent.
- Bevacizumab intravitreal injection (TLS Red) additional indications on the formulary for: radiation maculopathy, neovascular glaucoma, pre-vitrectomy and corneal neovascularisation.
- Nicardipine intravenous infusion (TLS Red) for treatment of acute hypertension in critical care/intensive care units where labetalol/GTN is not effective or contraindicated or most suitable.
Traffic Light Status Changes
Anastrozole now TLS Amber Specialist Recommended. Duration of therapy for chemoprophylaxis is 5 years. Duration of therapy for cancer treatment is as advised by the oncology specialist team.
Tamoxifen now TLS Amber Specialist Recommended. Duration of therapy for chemoprophylaxis is 5 years. Duration of therapy for cancer treatment is as advised by the oncology specialist team.
Letrozole now TLS Amber specialist Recommended.
Exemestane now TLS Amber specialist Recommended.
Other decisions
- Valproate
- Small update to combined adult and paediatric SCP approved
- TLS for neuropathic pain discussed. Agreed neuropathic pain indication can be removed for new adult patients. Patients currently prescribed valproate for neuropathic pain may continue without change until they and their NHS clinician consider it appropriate to stop.
- Acamprosate
revised wording to clarify position:
• Acamprosate is indicated as therapy to maintain abstinence in alcohol-dependent patients and should be prescribed for up to 6 months with supportive counselling.
• Prescribing can be initiated by a GP either as part of a primary care alcohol detox pathway or following the advice of a Specialist. Prescribing should be continued in primary care once initiated by a Specialist. Detailed advice will be provided where appropriate. - Aripirazole- formulary amended to clarify that formulary position applies to oral formulation only
- Sativex added to the formulary as TLS Red
- Dithrocream has been discontinued and removed from formulary